Drone reveals scale of major hospital's rotten roof
A "design defect" meant driving rain was being trapped beneath tonnes of concrete tiles, rotting the wooden battens that held them up.
"There was no structural separation between the tiles and the patients in the beds down below, so it was pretty serious," said architect Jeoff Houlker, who believes the situation could have become "catastrophic" over the winter.
A critical incident was declared at the hospital in Bridgend, south Wales, and the entire first floor - including the intensive care unit (ICU) - was evacuated.
Hospital's rotting roof declared critical incident
Hospital's rotten roof repair to cost £20m
Almost overnight, Cwm Taf Morgannwg health board lost 10 wards, eight theatre spaces and had to relocate the ICU at a time of huge pressure on Welsh hospitals to tackle lengthy waiting lists.
The rapid "decant of services" meant the nine-bed ICU was given a temporary new home in the space previously occupied by eye theatre.
That in turn had to move off-site, to a different hospital – just one example of the huge ripple felt across the entire health board's estate.
Dr Gareth Roberts, clinical lead for critical care, said a big part of the move was keeping patients' relatives informed and reassured.
The roof has now been replaced over the original ICU, but work continues to refurbish the unit itself.
Walking around the shell of the ward for the first time since it was evacuated, Dr Roberts admitted feeling a mix of emotions.
"I don't think it's what the NHS deserves or needs," said Dr Roberts.
"It deserves proactive work rather than reactive. But I'm glad we've done everything we have safely, and the last few months have shown we are able to be nimble, safe and dynamic."
Wales-wide efforts to provide more hospital care at home enabled some patients to be discharged, but it is has been hard to escape the impact on planned care.
"The areas that have been a particular challenge are endoscopy, where we've lost capacity, and planned orthopaedic operations," said Paul Mears, chief executive of the health board.
Mr Mears said they had arranged for some additional capacity at the nearby Prince Charles Hospital and Royal Glamorgan Hospital.
"It's put us back by a few months, but we want to get back on track as quickly as possible because we recognise obviously there are patients who have been waiting a long time," he added.
Head of nursing, Catherine Theron, said it was crucial to reassure staff and the local community that the changes were only temporary.
"We had a very short time frame to move everyone immediately," she said.
"It's really shown the resilience of our teams and the community of this hospital. Everyone has pulled together."
If there is a silver lining to the upheaval, the closure of a large part of the hospital has meant essential updates to fire safety and IT work could be addressed.
Large parts of the new roof are also now covered in solar panels which – at full capacity – will serve half the hospital's energy needs.
Across Wales the total maintenance backlog for the NHS estate is approaching £977m - with the vast majority deemed to be high or significant risk.
Health board boss Mr Mears said managing the day-to-day business of healthcare alongside building repairs was a constant juggle.
"It does mean you have to make difficult choices," he said, adding they were grateful for government assistance and plans to increase the NHS capital budget next year.
"There is always going to be trade-offs. But it's also about looking at how you can potentially come out of some of the most substandard estate and think about maybe consolidating estate, or creating new, to try and mitigate the risks."
The hospital's roof repair work totals nearly £28m and is being funded by the Welsh government.
The first phase of the new 10,000 sq m roof is complete, meaning maternity, neo-natal care and the special care baby unit will return to the site within a few weeks.
The full repairs are expected to be finished by August.
First-time mum worried as maternity unit closes
Hospital's rotting roof declared critical incident
Hospital's rotten roof repair to cost £20m

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Thousands of women with advanced breast cancer could be denied life-extending drugs because of the 'unfair' way they are assessed for use on the health service, a charity has warned. Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'
Yahoo
4 hours ago
- Yahoo
Record number of NHS operations given in private hospitals
The number of NHS operations carried out in private hospitals or clinics has hit a record high, according to new analysis. Data from the Independent Healthcare Providers Network (IHPN) show that private hospitals delivered the equivalent of 2,859 NHS procedures every working day in April – an increase of over 60% compared to the same month in 2019. It said that almost one in five NHS operations in England are carried out in private hospitals and clinics. Overall, the independent sector is delivering 10% of all NHS planned care, up from 8% before the Covid-19 pandemic, the IHPN said. The IHPN also said that the number of referrals it had received has also reached a record high – with private providers receiving 7,162 referrals each working day in April. Official NHS data show that the waiting list for routine hospital treatment in England has fallen to its lowest level for two years. An estimated 7.39 million treatments were waiting to be carried out at the end of April, relating to 6.23 million patients – down from 7.42 million treatments and 6.25 million patients at the end of March. The Government has set out plans to send more patients for treatment in private hospitals to slash waiting lists. David Hare, chief executive of the IHPN, said: 'This latest data shows the independent sector's increasingly pivotal role in delivering frontline NHS care – delivering record levels of NHS care which will be instrumental in helping the Government to meet their key milestone to ensure 92% of patients are treated within 18 weeks by the end of this Parliament. 'While this is a clear sign of welcome progress in tackling NHS waiting lists, the sector is committed to building on this already impressive achievement and will be working with the Government to ensure the principles contained in the recent NHS and Independent Sector Partnership Agreement are fully embedded – enabling patients to have a greater choice over their care so they can get the treatment they need, when they need it.'
Yahoo
8 hours ago
- Yahoo
AstraZeneca may quit London stock market
AstraZeneca's chief executive has discussed shifting the company's stock market listing to the US in a move that would deal a huge blow to London. Sir Pascal Soriot has reportedly spoken of his desire to move the listing to the US in private meetings and suggested moving AstraZeneca's domicile away from the UK. Shares jumped almost 3pc following the report in The Times, which indicates that investors support the idea. AstraZeneca leaving would be a huge blow to the London Stock Exchange, which has been reeling from a string of departures and a dearth of new listings. It would also be a setback for the Government, which is expected to unveil its long-awaited life sciences sector plan within days. AstraZeneca is the largest listed business in London and Britain's biggest drugmaker, with its headquarters in Cambridge. Sir Pascal has been increasingly critical of red tape in the UK and the charges paid by drugmakers to the NHS. Last year, pharmaceutical companies paid the NHS £3bn under a drug rebate scheme meant to stop the health service's costs spiralling out of control. However, the cost of the scheme to drugmakers has ballooned since the pandemic. Sir Pascal has been among those to criticise the scheme, telling the Government that it should 'continue working on improving the environment to attract investment'. AstraZeneca has snubbed the UK for investment in recent years amid concerns over the operating environment. In 2023, it said it had overlooked Britain for a new $400m (£320m) drug factory because of its 'discouraging' tax regime. Last year, AstraZeneca axed plans for a separate £450m vaccine factory in Liverpool after the Government lowered the financial support available. Speaking in April, Sir Pascal said investment would go towards countries that favour AstraZeneca by buying its cutting-edge medicines. He said: 'Companies will follow where they feel welcome. In our industry, it's a question of where do we think patients will be able to benefit from our products and we invest there.' The prospect of AstraZeneca quitting the London market and shifting its headquarters will pile pressure on ministers to improve the UK for drug companies. Labour is this week expected to outline its strategy to turn Britain into the world's third-largest pharma superpower after the US and China. The strategy has already been hit by setbacks, with ministers last week scrambling to agree a crucial deal on NHS drug charges that was meant to be at the centre of its plan to boost growth. AstraZeneca's exit would also ramp up pressure on the London Stock Exchange, which has been hit by a raft of high-profile exits, including Paddy Power owner Flutter and drugs giant Indivior. Any move by AstraZeneca would require board approval. The company declined to comment. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data